论文部分内容阅读
目的:研究乳腺癌中bcl-2蛋白表达与患者生存期及其组织学分级、雌激素受体(ER)、p53、c-erbB-2等影响预后因素的关系。方法:采用免疫组化LSAB法检测bcl-2、ER、p53及c-erbB-2的表达,并分析其相关性及其与预后的关系。结果:bcl-2阳性表达率为50.27%(92/183),其表达与乳腺癌组织学分级、ER状态呈明显正相关,与p53及c-erbB-2表达呈明显负相关;bcl-2阴性者其总生存率及无瘤生存率均明显低于bcl-2阳性者。结论:bcl-2蛋白阴性的乳腺癌患者预后不好,这可能与bcl-2失表达肿瘤中,p53蛋白聚积、c-erbB-2过度表达以及ER的缺失有关;免疫组化检测bcl-2表达可为预测乳腺癌患者预后及选择内分泌治疗提供一个有实用价值的指标。
OBJECTIVE: To investigate the relationship between the expression of bcl-2 protein and prognosis in patients with breast cancer and their histological grade, estrogen receptor (ER), p53, c-erbB-2 and so on. Methods: The expressions of bcl-2, ER, p53 and c-erbB-2 were detected by immunohistochemical LSAB method and the relationship between them and the prognosis was analyzed. Results: The positive rate of bcl-2 was 50.27% (92/183). The expression of bcl-2 was positively correlated with histological grade and ER status, but negatively correlated with the expression of p53 and c-erbB- Negative overall survival and tumor-free survival rates were significantly lower than bcl-2-positive. Conclusion: The prognosis of patients with bcl-2 negative breast cancer is not good, which may be related to the accumulation of p53 protein, the overexpression of c-erbB-2 and the deletion of ER in the tumor with bcl-2 overexpression. The expression of bcl-2 Expression can provide a valuable indicator for predicting the prognosis of breast cancer patients and selecting endocrine therapy.